<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003939</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62982-16993</org_study_id>
    <secondary_id>EORTC-62982</secondary_id>
    <nct_id>NCT00003939</nct_id>
  </id_info>
  <brief_title>Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma</brief_title>
  <official_title>Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients
      who have advanced soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the therapeutic activity of ecteinascidin 743 in patients with
      advanced soft tissue sarcomas. II. Determine the duration of response in these patients. III.
      Determine the acute side effects in these patients.

      OUTLINE: This is a multicenter study. Patients receive ecteinascidin 743 (ET-743) IV over 24
      hours every 3 weeks. Treatment continues for at least 2-6 courses in the absence of disease
      progression or unacceptable toxicity. Patients are followed every 6 weeks until disease
      progression and every 12 weeks after disease progression.

      PROJECTED ACCRUAL: Approximately 28-44 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">November 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">132</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trabectedin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven soft tissue sarcoma, including the following
        cell types: Malignant fibrous histiocytoma Liposarcoma Rhabdomyosarcoma Synovial sarcoma
        Malignant paraganglioma Fibrosarcoma Leiomyosarcoma Angiosarcoma including
        hemangiopericytoma Neurogenic sarcoma Unclassified sarcoma Miscellaneous sarcoma including
        mixed mesodermal tumors of the uterus Cell types NOT allowed: Malignant mesothelioma
        Chondrosarcoma Neuroblastoma Osteosarcoma Ewing's sarcoma Embryonal rhabdomyosarcoma
        Measurable lesion with evidence of progression within 6 weeks prior to study (osseous
        lesions, hepatomegaly, lymphedema, ascites, and pleural lesions are not considered
        measurable) No symptomatic or known CNS metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: WHO 0-1 Life expectancy: Not
        specified Hematopoietic: Neutrophil count at least 2,000/mm3 Platelet count at least
        100,000/mm3 Hepatic: Bilirubin no greater than 1.75 mg/dL Albumin at least 2.5 g/dL AST and
        ALT less than 1.5 times upper limit of normal (ULN) (2.5 times ULN if liver metastasis
        present) Alkaline phosphatase less than 2.5 times ULN No other significant hepatic disease
        (e.g., active hepatitis, cirrhosis, etc.) Renal: Creatinine no greater than 1.36 mg/dL OR
        Creatinine clearance at least 60 mL/min Cardiovascular: No prior cardiovascular disease
        Other: No other severe medical illness No psychosis No prior or concurrent second primary
        malignant tumors, except adequately treated carcinoma in situ of the cervix or basal cell
        carcinoma Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
        since prior chemotherapy No more than 1 prior regimen of combination chemotherapy OR No
        more than 2 prior single agent regimens No other concurrent chemotherapy Endocrine therapy:
        Not specified Radiotherapy: No prior radiotherapy to sole index lesion No concurrent
        radiotherapy Surgery: Not specified Other: No other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Le Cesne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <reference>
    <citation>Therasse P, Le Cesne A, Van Glabbeke M, Verweij J, Judson I; EORTC Soft Tissue and Bone Sarcoma Group. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer. 2005 Jul;41(10):1426-30.</citation>
    <PMID>15919202</PMID>
  </reference>
  <results_reference>
    <citation>Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005 Jan 20;23(3):576-84. Erratum in: J Clin Oncol. 2005 Aug 1;23(22):5276.</citation>
    <PMID>15659504</PMID>
  </results_reference>
  <results_reference>
    <citation>Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, van Glabbeke M, Judson I. A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2004 Jun;40(9):1327-31.</citation>
    <PMID>15177491</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Cesne A, Judson I, Blay JY, et al.: Phase II study of ET-743 in advanced soft tissue sarcoma (ASTS) in adults: a STBSG-EORTC trial. [Abstract] Proceedings of the American Society of Clinical Oncology 19: A-2182, 2000.</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>adult alveolar soft-part sarcoma</keyword>
  <keyword>adult epithelioid sarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>adult malignant mesenchymoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>uterine carcinosarcoma</keyword>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>endometrial stromal sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

